🧬 1. Hemophilia – Disease Background (Context for Everything)

Hemophilia is a genetic bleeding disorder where the body cannot form stable blood clots.

Key idea:

• You don’t bleed more often, but when you do → bleeding doesn’t stop
• Caused by missing clotting factors:
  • Hemophilia A → missing Factor VIII
  • Hemophilia B → missing Factor IX

Severity levels:

• Severe: <1% activity → spontaneous bleeding
• Moderate: 1–5%
• Mild: 5–40%

👉 Consequence:

• Continuous micro-bleeding in joints → inflammation → joint destruction
• Leads to:
  • Chronic pain
  • Reduced mobility
  • Joint replacements

🧪 2. Blood Coagulation Cascade (CORE CONCEPT)

🧩 What is it?

A biochemical amplification cascade where inactive proteins are sequentially activated to form a clot.

🔥 Key principle:

A small signal → generates a huge output (thrombin + fibrin)

🧬 Mechanism:

• Cascade consists mainly of proteases (enzymes that cut proteins)
• Each step:
  • Inactive precursor (zymogen) → activated enzyme
  • Activated enzyme → activates the next

💡 Why a cascade?

• Amplification:
  • One activated factor → activates many downstream molecules
• Speed + efficiency

⚠️ Critical point:

• Highly regulated system
  • Too little → bleeding (hemophilia)
  • Too much → thrombosis (clots everywhere → deadly)

🧠 Important insight (from lecture):

• You cannot replace this system with small molecules
  • Because:
    • It relies on proteolytic activity + spatial organization
    • Not just simple binding

✂️ 3. Proteolytic Activation of Enzymes

🧬 What does it mean?

A protein is activated by cutting (cleaving) specific peptide bonds

Before:

• Inactive form = zymogen

After cleavage:

• Conformational change → active enzyme

🔬 Example in coagulation:

• Factor X → Factor Xa (active protease)
• Thrombin generation depends on these activations

💡 Why use proteolysis?

1. Irreversible activation
   • Once active → stays active
2. Fast response
3. Amplification
4. Tight control
   • Only activated when needed

⚠️ Design implication (important):

• You can’t mimic proteolysis easily with drugs
• That’s why:
  • Therapeutics use proteins or antibodies, not small molecules

🧠 4. Key Bottleneck in Hemophilia

🚨 Central problem:

Patients cannot efficiently generate Factor Xa → thrombin

Why?

• Missing Factor VIII or IX disrupts:
  • Activation of Factor X

💡 Insight:

The cascade fails at a critical amplification step

💊 5. Therapeutic Strategies (Conceptual Overview)

Traditional:

• Replace missing factor (Factor VIII or IX)

Problems:

• Expensive
• Short half-life
• Immune response (inhibitors)

⚠️ Inhibitor problem:

• Immune system attacks therapy
• Result:
  • Treatment becomes ineffective
  • Disease becomes more severe

🧬 6. Antibody-Based Therapy (VERY IMPORTANT CONCEPT)

💡 Idea:

Instead of replacing missing proteins → bypass them

🧠 Mechanism:

Design a bispecific antibody that:

• Binds Factor IXa
• Binds Factor X

👉 Brings them together → mimics Factor VIII function

🎯 Result:

• Restores activation of Factor X
• Enables clot formation

⚠️ Design challenge:

Balance affinity:

🔬 Optimization strategy:

• Reduce affinity to Factor X
• Increase stimulation of Factor IXa
• Iterative mutation + screening

📈 Outcome:

• Massive increase in activity (~1000-fold improvements)
• Effective thrombin generation

💡 7. Developability of Therapeutic Proteins (CRITICAL TOPIC)

🧠 What is “developability”?

How suitable a protein is as a drug candidate

🧪 Factors to consider:

1. Stability

• Large proteins (e.g., Factor VIII ~285 kDa) are:
  • Unstable
  • Sticky (“snot protein”)
  • Hard to formulate

2. Dose requirements

• Factor VIII → low concentration needed
• Factor IX → higher concentration needed

👉 Impacts:

• Manufacturing cost
• Feasibility

3. Size

• Large proteins:
  • Poor tissue penetration
  • Difficult delivery

4. Immunogenicity

• Risk of antibodies against drug

5. Half-life

• Determines dosing frequency

6. Route of administration

• IV (inconvenient)
• Subcutaneous (preferred)
• Oral (ideal but very hard for proteins)

💡 Key takeaway:

Drug design is NOT just about function → it’s about practical usability

🚀 8. Advanced Protein Engineering Strategies

🧬 1. Directed evolution

• Random mutations → screening → optimization

🧬 2. Structure-guided design

• Use structural data to guide mutations

👉 Best approach = combination of both

🧪 Libraries:

• Thousands of variants tested
• Selection based on:
  • Activity
  • Binding
  • stability

🧬 9. Half-Life Extension Strategies

🧠 Problem:

Proteins are quickly degraded

💡 Solution:

Attach fatty acids (e.g., C16, C18)

Mechanism:

• Bind to albumin
• “Hitchhike” in circulation

Result:

• Dramatically increased half-life

💊 10. Oral Protein Delivery (Breakthrough Concept)

🚨 Challenge:

Proteins are destroyed in stomach

💡 Solution:

Use absorption enhancers (e.g., SNAC)

Function:

• Protect protein from degradation
• Enable absorption through gut

Outcome:

• Oral delivery becomes possible
• Major improvement in patient compliance

🧪 11. Clinical Development Principles

Phase 1:

• Healthy volunteers
• Safety + pharmacokinetics

Phase 2/3:

• Patients
• Efficacy

⚠️ Important constraint:

• Must monitor for:
  • Over-coagulation (clots)
  • Under-coagulation (bleeding)

📊 12. Clinical Outcomes (Conceptual)

Goals:

• Reduce bleeding frequency
• Improve clot quality
• Improve quality of life

Observations:

• Patients:
  • Move from severe → near-normal clotting
  • Bleeding events drop dramatically

🧠 13. Systems Thinking Insight (VERY IMPORTANT)

Blood coagulation is:

• A network, not just a pathway

Therapeutic strategies:

1. Replace missing component
2. Bypass pathway
3. Inhibit inhibitors
4. Enhance weak steps

💡 Key insight:

Multiple intervention points exist → drug design is about choosing the optimal leverage point

⚙️ 14. Practical Innovation Insight

Not all innovation = curing disease

Example:

• Switching from:
  • IV injections → subcutaneous pen

👉 Huge improvement in patient life

💡 Lesson:

Convenience = major therapeutic value

🧠 Final Takeaways

Core principles:

• Coagulation = proteolytic amplification cascade
• Hemophilia = failure of amplification step
• Drugs must:
  • Restore function
  • Be stable
  • Be deliverable
  • Be affordable

Key conceptual shift:

• From replacement therapy → functional mimicry (antibodies)

Big picture:

Successful therapeutics sit at the intersection of:

• Biology
• Engineering
• Pharmacology
• Practical usability

🧬 Discovery of a Novel FVIIIa Mimetic Using Camelid VHH Domains

This part builds directly on the earlier antibody concept but pushes it further using camelid single-domain antibodies (VHHs). The goal is still the same:

Replace the function of Factor VIIIa (FVIIIa) by bringing Factor IXa and Factor X together.

🐪 1. Why Camelid VHH Domains?

🧠 What are VHHs?

VHHs are single-domain antibodies derived from camelids such as:

• llamas
• alpacas

Unlike human antibodies:

• Normal antibodies = heavy + light chains
• Camelid antibodies = heavy chain only
• The binding part = VHH (very small domain)

💡 Key advantages:

• Very small (~15 kDa) compared to full antibodies (~150 kDa)
• Highly stable
• Can bind hidden or tight epitopes
• Easier to engineer into multispecific constructs

👉 Perfect for designing synthetic protein tools

🧪 2. How They Use Llamas and Alpacas

🧬 Step 1: Immunization

• Llama/alpaca is injected with target proteins:
  • Factor IXa
  • Factor X

👉 Animal immune system generates VHH antibodies against these targets

🧫 Step 2: Isolation of VHH Genes

• Blood is collected
• B-cells are isolated
• Genes encoding VHH domains are extracted

🧬 Step 3: Library Construction

• VHH sequences are inserted into display systems:
  • Often phage display

👉 Creates a large library (~hundreds to thousands of variants)

🔍 Step 4: Screening

• Screen for VHHs that bind:
  • Factor IXa
  • Factor X

👉 In your file:

• ~350 VHH candidates identified

🧠 Key idea:

The animal does the initial diversity generation, researchers do the selection

🔗 3. Building the FVIIIa Mimetic

💡 Strategy:

Combine two VHHs into one molecule:

• One VHH → binds Factor IXa
• One VHH → binds Factor X

👉 Result: bispecific molecule

🧬 Functional outcome:

• Forces IXa and X into proximity
• Mimics FVIIIa cofactor activity
• Enables:
  • Factor X → Xa activation
  • Thrombin generation → clotting

⚙️ 4. Molecular Optimization via Mutagenesis

This is where most of the engineering effort happens.

🧪 Step 1: Initial candidates are NOT optimal

Problems:

• Weak activity
• Poor affinity balance
• Suboptimal kinetics

🔬 Step 2: Mutagenesis strategies

1. Random mutagenesis

• Introduce random mutations across VHH sequence
• Generates diversity

👉 Pros:

• Explores unexpected beneficial mutations 👉 Cons:
• Requires large screening effort

2. Site-directed mutagenesis

• Target specific residues
• Based on:
  • structural data
  • binding interface knowledge

👉 Pros:

• More controlled 👉 Cons:
• Can miss non-obvious improvements

3. Iterative evolution (key concept)

• Mutation → screening → selection → repeat

👉 This is essentially directed evolution

🔁 Optimization cycles

From your lecture:

• Start with baseline molecule
• Perform multiple rounds of:
  • mutation
  • screening
  • recombination

📈 Measured improvements:

• Lower EC50 (higher potency)
• Increased thrombin generation
• Better kinetic behavior

💡 Critical insight:

Important mutations are NOT always at the binding site Many occur elsewhere and affect:

• flexibility
• orientation
• stability

⚠️ 5. Key Design Constraints

🔗 Binding affinity balance

Must be:

• Strong enough → bring IXa + X together
• Weak enough → allow turnover

👉 Otherwise:

• Molecule “locks” → no catalytic cycling

⚡ Catalytic efficiency

• Must allow:
  • binding → activation → release → repeat

🧬 Spatial orientation

• Correct geometry is essential
• Even if both targets bind → wrong angle = no activity

🧪 6. Additional Engineering: Half-Life Extension

Problem:

Small VHHs are cleared quickly

Solution:

Attach fatty acid chains

• Enables binding to albumin
• Extends circulation time

Observation from lecture:

• Different fatty acids (C16 vs C18) → huge impact on half-life
• Not always intuitive → must be tested experimentally

💊 7. Final Molecule: “Inno8” Concept

Features:

• Bispecific VHH-based FVIIIa mimetic
• Small and stable
• Enhanced potency vs earlier antibodies
• Potential for oral delivery (with SNAC)

Functional outcome:

• Restores clotting in hemophilia patients
• Can outperform existing therapies in:
  • potency
  • dosing convenience

🧠 8. Big Conceptual Takeaways

🔬 1. Biology + engineering

• Natural immune system → generates diversity
• Engineering → refines it

🧬 2. Directed evolution is essential

• Rational design alone is insufficient
• Combination approach works best

⚙️ 3. Function ≠ binding alone

• Need:
  • correct geometry
  • dynamic interactions
  • catalytic turnover

💡 4. Small scaffolds = big potential

• VHH domains enable:
  • compact designs
  • novel delivery routes
  • high engineering flexibility

🔑 Final Summary

The discovery pipeline:

1. Immunize camelid (llama/alpaca)
2. Extract VHH sequences
3. Build and screen libraries
4. Combine VHHs into bispecific molecules
5. Optimize via iterative mutagenesis
6. Engineer pharmacokinetics (half-life, delivery)